Young age and autologous stem cell transplantation are associated with improved survival in newly diagnosed multiple myeloma
ABSTRACT Background: Multiple myeloma is a disease of the elderly. However, 40% of patients are diagnosed before 65 years old. Outcomes regarding age as a prognostic factor in MM are heterogeneous. Method: We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. Main results: The frequency of multiple myeloma in those younger than 66 years was 53.2%. Younger patients presented with a more aggressive disease, more advanced Durie-Salmon stage (85.3% vs 73.5%; p = 0.013), extramedullary disease (12.7% vs 0%; p < 0.001), osteolytic lesions (78.7% vs 57.6%; p < 0.001) and bone plasmacytoma (25.3% vs 11.4%; p = 0.003). In spite of this, the overall response rate was similar between groups (80.6% vs 81.4%; p = 0.866). The overall survival was significantly longer in young patients (median, 65 months vs 41 months; p = 0.001) and higher in those who received autologous hematopoietic stem cell transplantation. The main cause of death was disease progression in both groups. Multivariable analysis revealed that creatinine ≥2 mg/dl, extramedullary disease, ≤very good partial remission and non-autologous hematopoietic stem cell transplantation are independent risk factors for shorter survival. Conclusion: Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation.
Main Authors: | Bove,Virginia, Garrido,David, Riva,Eloisa |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular (ABHH)
2021
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2531-13792021000300295 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prospective identification of potential factors influencing stem cell mobilization and the necessity for plerixafor use in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation
by: Ray,Gopal Krushna, et al.
Published: (2021) -
The role of thalidomide as maintenance after autologous stem cell transplantation in multiple myeloma
by: Maiolino,Angelo
Published: (2009) -
Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients
by: Etto,Leina Y, et al.
Published: (2011) -
Outcomes of autologous transplantation for multiple myeloma according to different induction regimens
by: Crusoe,Edvan de Queiroz, et al.
Published: (2014) -
Autologous stem-cell transplantation for multiple myeloma: a Brazilian institution experience in 15 years of follow-up
by: Todaro,Juliana, et al.
Published: (2011)